ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
about
BRCAness: finding the Achilles heel in ovarian cancerTrial watch - inhibiting PARP enzymes for anticancer therapyTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyPARP inhibitors in the management of breast cancer: current data and future prospectsTargeting ATM-deficient CLL through interference with DNA repair pathwaysPARPs and the DNA damage responseLow ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineAnti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsDNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin.Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.Targeting poly(ADP-ribose) polymerase activity for cancer therapy.Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM geneATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.ATM signalling and cancer.Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instabilityATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast CancersA new arylbenzofuran derivative functions as an anti-tumour agent by inducing DNA damage and inhibiting PARP activity.Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virusMultigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.PARP1 Inhibitors: antitumor drug design.Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair.Molecular pathogenesis of mantle cell lymphoma.Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.Predicting PARP inhibitor sensitivity and resistance.Saccharomyces cerevisiae genetics predicts candidate therapeutic genetic interactions at the mammalian replication fork.Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer
P2860
Q24630872-2F6155AC-383D-4E1F-A183-71B3D2221473Q26745673-B31679B7-CF45-4548-AA04-40D7D12DF821Q26745686-E4EBCB9F-C231-4005-A120-A75C01A2B34CQ26798352-B6751989-22E6-4C08-8BE4-6343DD57AEB1Q26822592-0D059620-7F77-45CB-9F75-A865A5A5289EQ26859010-4DA65A9E-0D68-4212-B89E-0B6EB8E3F0FAQ27853007-0B951C1F-A7B1-4A20-9D11-D01A4CBAB062Q28072204-F71DC32E-7C77-462F-94AD-E14787AC4AA1Q33557916-FE71464D-07E9-4177-B2B3-C35B491526EEQ33618910-26F60343-CCF9-45EE-9B05-83254F405ABFQ33834990-1CB84B9B-CF67-4BAE-B2C8-002EC9EFF566Q33882519-D63268F2-5621-4237-A865-D9EE0EE15875Q34204660-D3FC49BF-A011-4F2D-9481-888A8131C2DEQ34224906-FDD6A382-A85F-4B3B-B81A-D7A132BCA0D1Q34249365-E476B988-2A9E-41EE-A67E-FA06FED4A482Q34357377-A9A5E70C-3FEA-40AF-BBC1-143F30425BCEQ34602683-4B9EE73C-258F-437F-9939-7CE7BC8E597BQ35051154-1A8821F6-6585-406E-99E4-B9CE008A9212Q35051517-E4FC6079-D700-4674-B064-4E2C2742DBE9Q35064299-9FA3C8B7-C930-43F5-A71F-D6C088D7E29BQ35198369-53297E67-9D15-4880-B924-54518FAFB77DQ35255891-A200E448-9670-434C-AA53-689364FB3227Q35403658-8DB00C6C-7403-451C-8B24-71336E9B434DQ35534509-ED72CAAE-4F79-4A40-8BBE-59D5E03EBF9FQ35665705-DA61E374-7182-4E5D-B3D2-16263F93AB56Q35681896-2A31D8FE-2035-4B98-9A64-9DB7542EBAF7Q35879098-375730FF-D3EA-469E-9E05-E2877806DA83Q35922047-8549CEC3-E4CB-4662-96B6-0F763AE119FFQ36098650-11AF0B19-57EA-4A99-A11F-798DDC03C71DQ36129160-4F045B07-0F15-40B2-8C7D-F2A066F00CF0Q36175159-30493519-0254-484A-B44E-5C0E19E91086Q36195450-9B2DDA8F-5FFB-4B97-9172-2EB427C4283DQ36238650-BC3ED87D-25BF-4888-8195-DC6415126D09Q36283677-C2FB81CB-9639-40A7-86C1-EB6EBE3C7294Q36290246-B2A701CA-7E64-47F6-BD27-E24D511344E4Q36294441-3545B997-14CF-415F-AF8A-CF5CA5C4C6A4Q36389184-7831272B-CD2B-43ED-BC6E-F1AD49331044Q36472222-5186E5A0-8233-40EF-B6E1-938F3B82F600Q36588976-97D4230B-35FB-42D4-9EF1-0DD2AA2844BFQ36776802-DD1150F8-BE40-4532-8B6F-5DA45F297FBB
P2860
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ATM deficiency sensitizes mantle cell lymphoma cells to poly
@nl
ATM deficiency sensitizes mant ...... bose) polymerase-1 inhibitors.
@en
type
label
ATM deficiency sensitizes mantle cell lymphoma cells to poly
@nl
ATM deficiency sensitizes mant ...... bose) polymerase-1 inhibitors.
@en
prefLabel
ATM deficiency sensitizes mantle cell lymphoma cells to poly
@nl
ATM deficiency sensitizes mant ...... bose) polymerase-1 inhibitors.
@en
P2093
P2860
P1476
ATM deficiency sensitizes mant ...... bose) polymerase-1 inhibitors.
@en
P2093
Alberto Zamò
Ali G Turhan
Chris T Williamson
D Gwyn Bebb
Huong Muzik
Mark J O'Connor
Susan P Lees-Miller
P2860
P304
P356
10.1158/1535-7163.MCT-09-0872
P577
2010-02-02T00:00:00Z